Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
105.42
+5.12 (5.10%)
At close: Nov 21, 2025, 4:00 PM EST
106.55
+1.13 (1.07%)
After-hours: Nov 21, 2025, 7:59 PM EST
Guardant Health Revenue
Guardant Health had revenue of $265.20M in the quarter ending September 30, 2025, with 38.50% growth. This brings the company's revenue in the last twelve months to $902.57M, up 30.38% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$902.57M
Revenue Growth
+30.38%
P/S Ratio
14.50
Revenue / Employee
$446,595
Employees
2,021
Market Cap
13.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GH News
- 2 days ago - These 15 stocks are still showing momentum — and a market-beating edge - Market Watch
- 4 days ago - 6 Healthcare Stocks With Strong Upward Momentum - Benzinga
- 10 days ago - Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access - Business Wire
- 12 days ago - Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring - Business Wire
- 15 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 16 days ago - Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 16 days ago - New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response - Business Wire
- 17 days ago - Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients - Business Wire